HMG-CoA Reductase Inhibitors in Chronic Heart Failure: Potential Mechanisms of Benefit and Risk

Author： Laufs Ulrich   Custodis Florian   Böhm Michael  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.66, Iss.2, 2006-01, pp. : 145-154

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia

By Penzak Scott R   Chuck Susan K  

Expert Opinion on Drug Safety, Vol. 1, Iss. 1, 2002-05 ,pp. : 5-17

Informa Healthcare

Access to resources Recommend Favorite

HMG-CoA reductase inhibitors/paracetamol: Liver failure: 2 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1202, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 7, Iss. 1, 2009-03 ,pp. : 1-26

Bentham Science Publishers

Access to resources Recommend Favorite

The effect of HMG-CoA reductase inhibitors on chronic allograft rejection

By Jones T.  

Expert Opinion on Emerging Drugs, Vol. 6, Iss. 1, 2001-04 ,pp. : 95-109

Informa Healthcare

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitors as Immunomodulators: Potential Use in Transplant Rejection

By Raggatt L.J.   Partridge N.C.  

Drugs, Vol. 62, Iss. 15, 2002-01 ,pp. : 2185-2191

Adis International

Access to resources Recommend Favorite